Previous close | 3.0300 |
Open | 4.1000 |
Bid | 0.4500 |
Ask | 1.4500 |
Strike | 7.50 |
Expiry date | 2024-05-17 |
Day's range | 3.0300 - 4.1000 |
Contract range | N/A |
Volume | |
Open interest | 25 |
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL-172154 continued to demonstrate an acceptable safety profile in combination with AZA – – EHA poster presentation to include additional data from the next planned data cutoff in the second quarter of 2024 – AUSTIN, TX and DURHAM, NC, May 14, 2024 (GLOBE NEWS
Shattuck Labs (STTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Shattuck Labs (STTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.